Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regorafenib - Bayer Healthcare

X
Drug Profile

Regorafenib - Bayer Healthcare

Alternative Names: BAY-734506; fluoro-sorafenib; Resihance; Stivarga

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer ARCAGY/GINECO Group; Bayer HealthCare; Bayer Zydus Pharma; Bristol-Myers Squibb; British Columbia Cancer Agency; Global Coalition for Adaptive Research; Jiangsu Hengrui Medicine Co.; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Ono Pharmaceutical; Spanish Cooperative Group for Digestive Tumour Therapy; University of Pittsburgh
  • Class Amides; Antineoplastics; Eye disorder therapies; Fluorobenzenes; Phenylurea compounds; Pyridines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Mitogen-activated-protein kinase 11-inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; TrkA receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastrointestinal stromal tumours; Liver cancer
  • Phase III Glioblastoma
  • Phase II Adenoid cystic carcinoma; Biliary cancer; Cholangiocarcinoma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • No development reported Acute myeloid leukaemia; Rhabdomyosarcoma
  • Discontinued Non-small cell lung cancer; Wet age-related macular degeneration

Most Recent Events

  • 23 Apr 2024 Bayer in collaboration with Merck Sharp & Dohme completes a phase II trial in Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, South Korea, Italy, Japan, Israel, Germany, USA (PO) (NCT04696055) (EudraCT2020-003555-16)
  • 13 Mar 2024 Regorafenib is still in phase I trials for Solid tumours (In children, In adolescents, Second-line therapy or greater) in UK, Spain and France (PO) (NCT02085148)
  • 13 Mar 2024 Bayer completes a phase I trial in Solid tumours (In children, In adolescents, Second-line therapy or greater) in UK, Spain, Italy and France (PO) (NCT02085148)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top